MAP1LC3A抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using MAP1LC3A mouse mAb (green) and negative control (red).    

  
  

MAP1LC3A (microtubule-associated protein 1 light chain 3 alpha), also known as LC3A, is a key autophagy-related protein involved in the formation and maturation of autophagosomes—double-membrane vesicles that degrade cellular components during autophagy. As a mammalian homolog of yeast Atg8. LC3A exists in two forms: cytosolic LC3-I and lipidated, membrane-bound LC3-II, the latter serving as a hallmark of autophagic activity. Antibodies targeting MAP1LC3A are widely used to monitor autophagy flux in research, as the conversion of LC3-I to LC3-II correlates with autophagosome formation.

These antibodies are essential tools in studying autophagy's role in physiological processes (e.g., nutrient deprivation, cellular stress) and diseases such as cancer, neurodegeneration, and infectious diseases. They enable detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry, helping visualize punctate LC3-II structures in cells. Specificity for LC3A is critical due to the existence of paralogs (LC3B, LC3C) with overlapping functions. Researchers often validate results using autophagy inhibitors (e.g., bafilomycin A1) or inducers (e.g., rapamycin) to confirm dynamic changes.

Dysregulation of LC3A-mediated autophagy is linked to pathological conditions, making its antibody a valuable asset in both mechanistic studies and therapeutic exploration targeting autophagy pathways.